ABSTRACT
Objective To observe the influence of Bailing capsule on the serum levels of hs-CRP,IL-18,TNF-α in patients with chronic kidney disease (CKD).Methods According to the digital table,56 CKD patients were randomly divided into the control group(28 cases) and treatment group(treated with Bailing capsules,28 cases).Meanwhile,20 healthy adults were selected as the normal controls.The blood concentrations of hs-CRP,IL-18,TNF -α,Scr and BUN were determined.Results The levels of hs-CRP,IL-18,TNF-α,Scr and BUN in CKD patients were significantly higher than those in the normal control [(5.99 ± 2.67) mg/L,(6.17-± 2.23) mg/L vs.(2.27 ± 2.16) mg/L,(44.43 ± 7.54)μg/L,(46.54 ± 8.63)μg/L vs.(11.42 ± 3.32) μg/L,(95.22 ± 34.65) ng/L,(105.48 ± 33.25) ng/L vs.(21.34-± 10.10) ng/L,(6.86 ± 2.97) mmol/L,(6.89 ± 2.85) mmol/L vs.(5.32 ±2.43) mmol/L,(98.47 ± 28.85) μmol/L,(95.46 ± 27.83) μmol/L vs.(75.45 ± 28.20)μmol/L,all P ＜ 0.05].The levels of hs-CRP,IL-18,TNF-α,Scr and BUN decreased after 12 weeks of conventional treatment (t =-0.22,-1.30,-1.76,-0.67,-1.16,all P ＞0.05),while those were significantly decreased with Bailing capsule treatment (t =-2.77,-3.81,-4.71,-2.06,all P ＜ 0.05).Conclusion The renal inflammation can be alleviated by Bailing capsule in CKD patients,which can slow the progression of CKD.
ABSTRACT
Objective To investigate the protective effect of pitavastatin on the patients with earlystage diabetic nephropathy and its mechanism.Methods Seventy cases of early-stage type 2 diabetic nephropathy were divided into pitavastatin group and regular treatment group by random digits table method with 35 cases each.Meanwhile,35 healthy adults with physical examination were recruited as control group.Before and after treatment in pitavastatin group and regular treatment group and on the day of physical examination in control group,the blood glucose,blood lipid,renal function,urinary albumin excretion rate (UAER),high-sensitivity C-reactive protein (hs-CRP),tumor necrosis factor (TNF)-α,interleukin (IL)-18 were determined and compared.Results Before treatment,the levels of total cholesterol (TC),low density lipoprotein cholesterol (LDL-C),triglycerides (TG),fasting blood sugar,2 h postprandial blood glucose,glycosylated hemoglobin,UAER,hs-CRP,TNF-α,IL-18,HDL-C were (5.74 ± 1.35) mmol/L,(3.73 ± 0.75) mmol/L,(3.46 ± 1.87) mmol/L,(10.25 ± 2.36) mmol/L,(15.59 ± 3.64) mmol/L,(8.67 ± 2.28)％,(124.2 ± 52.5) μg/min,(3.64 ± 1.48) mg/L,(43.74 ± 8.35) μ g/L,(113.43 ± 32.75) ng/L,(1.15 ± 0.36) mmol/L in regular treatment group and (5.93 ± 1.41) mmol/L,(3.68 ± 0.71) mmol/L,(3.29 ± 1.92) mmol/L,(10.48 ± 2.69) mmol/L,(16.04 ± 3.16) mmol/L,(9.48 ± 2.46)％,(116.2 ± 50.4) μ g/min,(3.48 ± 1.46) mg/L,(45.93 ± 9.41) μg/L,(120.68 ±35.20) ng/L,(1.18 ±0.35) mmol/L in pitavastatin group,and (4.57 ±0.83) mmol/L,(2.87 ± 0.64) mmol/L,(1.37 ± 0.58) mmol/L,(4.57 ± 1.37) mmol/L,(7.38 ± 1.30) mmol/L,(5.84 ± 1.57)％,(14.8 ± 9.4) μ g/min,(0.84 ± 0.52) mg/L,(10.42 ± 2.83) μ g/L,(20.84 ± 8.56) ng/L,(1.54 ± 0.39) mmol/L in control group.Before treatment,the levels of TC,LDL-C,TG,fasting blood sugar,2 h postprandial blood glucose,glycosylated hemoglobin,UAER,hs-CRP,TNF-α,IL-18 in regular treatment group and pitavastatin group were higher than those in control group,HDL-C was lower than that in control group,and there were significant differences(P ＜ 0.01).The levels of TC,LDL-C,TG were (4.42 ± 1.28),(3.20 ± 0.57),(2.02 ± 0.87) mmol/L after treatment in pitavastatin group,which were lower than those before treatment,and there were significant differences (P ＜ 0.01).The levels of UAER,hs-CRP,TNF-α,IL-18 were (88.3 ± 36.7) μ g/min,(2.54 ± 0.76) mg/L,(35.62 ± 5.28) μg/L,(83.23 ± 21.57) ng/L in regular treatment group and (64.8 ± 34.6)μ g/min,(2.19 ± 0.65) mg/L,(27.70 ± 7.58) μ g/L,(63.20 ± 18.67) ng/L in pitavastatin group after treatment,which were lower than those before treatment,but the decreased degree was obvious in pitavastatin group.Conclusions Pitavastatin can significantly reduce not only UAER,but also the levels of hs-CRP,TNF-α,IL-18,while effectively lower the blood lipid,in early diabetic nephropathy,which indicates that pitavastatin can reduce urine protein and protect renal function by inhibiting the inflammatory process.